On Monday, Cytokinetics Inc (NASDAQ: CYTK) opened lower -2.11% from the last session, before settling in for the closing price of $54.97. Price fluctuations for CYTK have ranged from $30.37 to $110.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 12.30% over the last five years. Company’s average yearly earnings per share was noted 6.15% at the time writing. With a float of $113.75 million, this company’s outstanding shares have now reached $117.66 million.
The firm has a total of 423 workers. Let’s measure their productivity. In terms of profitability, gross margin is -2886.73%, operating margin of -16148.37%, and the pretax margin is -17398.82%.
Cytokinetics Inc (CYTK) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cytokinetics Inc is 3.33%, while institutional ownership is 113.83%. The most recent insider transaction that took place on Oct 15 ’24, was worth 395,554. In this transaction EVP Research & Development of this company sold 7,300 shares at a rate of $54.19, taking the stock ownership to the 116,920 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 7,300 for $54.19, making the entire transaction worth $395,578.
Cytokinetics Inc (CYTK) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -1.35 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.74) by -0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Check out the current performance indicators for Cytokinetics Inc (CYTK). In the past quarter, the stock posted a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2022.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.37, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -4.87 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Analysing the last 5-days average volume posted by the [Cytokinetics Inc, CYTK], we can find that recorded value of 0.98 million was lower than the volume posted last year of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 46.71%. Additionally, its Average True Range was 1.84.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 47.28%, which indicates a significant increase from 41.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.53% in the past 14 days, which was lower than the 39.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $55.06, while its 200-day Moving Average is $63.24. Now, the first resistance to watch is $54.72. This is followed by the second major resistance level at $55.64. The third major resistance level sits at $56.42. If the price goes on to break the first support level at $53.02, it is likely to go to the next support level at $52.24. Should the price break the second support level, the third support level stands at $51.32.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are currently 104,854K shares outstanding in the company with a market cap of 6.33 billion. Presently, the company’s annual sales total 7,530 K according to its annual income of -526,240 K. Last quarter, the company’s sales amounted to 250 K and its income totaled -143,320 K.
